Skip to Content

Inlyta Approval History

  • FDA approved: Yes (First approved January 27th, 2012)
  • Brand name: Inlyta
  • Generic name: axitinib
  • Dosage form: Tablets
  • Company: Pfizer Inc.
  • Treatment for: Renal Cell Carcinoma

Inlyta (axitinib) is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma.

Development History and FDA Approval Process for Inlyta

Jan 27, 2012Approval FDA Approves Inlyta for Advanced Renal Cell Carcinoma
Dec  7, 2011FDA Advisory Committee Finds The Benefit/Risk Profile Of Axitinib In Previously Treated Advanced Renal Cell Carcinoma (RCC) To Be Favorable
Jul  7, 2011Pfizer Files With The FDA For Review Of Axitinib For Patients With Advanced Renal Cell Carcinoma

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.